

# Raisa S Pompe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6097756/publications.pdf>

Version: 2024-02-01

60  
papers

1,194  
citations

361413

20  
h-index

434195

31  
g-index

60  
all docs

60  
docs citations

60  
times ranked

1880  
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. <i>European Urology</i> , 2019, 76, 106-114.	1.9	77
2	External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. <i>European Urology</i> , 2019, 75, 896-900.	1.9	74
3	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. <i>European Urology</i> , 2017, 71, 330-336.	1.9	57
4	Postoperative complications of contemporary open and robot-assisted laparoscopic radical prostatectomy using standardised reporting systems. <i>BJU International</i> , 2018, 122, 801-807.	2.5	52
5	Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. <i>European Urology Focus</i> , 2017, 3, 615-620.	3.1	44
6	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. <i>Prostate</i> , 2018, 78, 469-475.	2.3	40
7	Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer. <i>Prostate</i> , 2019, 79, 1832-1836.	2.3	38
8	Local treatment for metastatic prostate cancer: A systematic review. <i>International Journal of Urology</i> , 2018, 25, 390-403.	1.0	37
9	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. <i>International Urology and Nephrology</i> , 2018, 50, 71-78.	1.4	37
10	Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN® Guideline. <i>Journal of Urology</i> , 2017, 198, 354-361.	0.4	36
11	Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. <i>International Urology and Nephrology</i> , 2017, 49, 2143-2149.	1.4	36
12	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. <i>Prostate</i> , 2017, 77, 686-693.	2.3	33
13	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. <i>BJU International</i> , 2018, 121, 592-599.	2.5	32
14	The impact of lymph node dissection and positive lymph nodes on cancer-specific mortality in contemporary pT2 non-metastatic renal cell carcinoma treated with radical nephrectomy. <i>BJU International</i> , 2018, 121, 383-392.	2.5	30
15	Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma. <i>World Journal of Urology</i> , 2017, 35, 1899-1905.	2.2	28
16	Survival benefit of local versus no local treatment for metastatic prostate cancer: Impact of baseline PSA and metastatic substages. <i>Prostate</i> , 2018, 78, 753-757.	2.3	27
17	Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. <i>World Journal of Urology</i> , 2019, 37, 469-479.	2.2	25
18	The Impact of Anxiety and Depression on Surgical and Functional Outcomes in Patients Who Underwent Radical Prostatectomy. <i>European Urology Focus</i> , 2020, 6, 1199-1204.	3.1	25

#	ARTICLE	IF	CITATIONS
19	The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2021, 4, 370-395.	5.4	25
20	Long-term cancer control outcomes in patients with biochemical recurrence and the impact of time from radical prostatectomy to biochemical recurrence. <i>Prostate</i> , 2018, 78, 676-681.	2.3	23
21	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. <i>World Journal of Urology</i> , 2018, 36, 7-13.	2.2	23
22	Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. <i>European Urology Focus</i> , 2019, 5, 807-814.	3.1	22
23	Does surgical delay for radical prostatectomy affect biochemical recurrence? A retrospective analysis from a Canadian cohort. <i>World Journal of Urology</i> , 2018, 36, 1-6.	2.2	20
24	Assessing the Outcome of Holmium Laser Enucleation of the Prostate by Age, Prostate Volume, and a History of Blood Thinning Agents: Report from a Single-Center Series of >1800 Consecutive Cases. <i>Journal of Endourology</i> , 2021, 35, 639-646.	2.1	20
25	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. <i>European Urology Oncology</i> , 2018, 1, 314-320.	5.4	19
26	The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. <i>European Urology Focus</i> , 2019, 5, 399-406.	3.1	19
27	Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 81.e17-81.e24.	1.6	18
28	Long-term oncological outcomes in patients with limited nodal disease undergoing radical prostatectomy and pelvic lymph node dissection without adjuvant treatment. <i>World Journal of Urology</i> , 2017, 35, 1833-1839.	2.2	17
29	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. <i>Journal of Sexual Medicine</i> , 2017, 14, 876-882.	0.6	16
30	Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 176-183.	1.9	16
31	The impact of time to catheter removal on short-, intermediate- and long-term urinary continence after radical prostatectomy. <i>World Journal of Urology</i> , 2018, 36, 1247-1253.	2.2	16
32	Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. <i>World Journal of Urology</i> , 2018, 36, 51-57.	2.2	16
33	Radical prostatectomy after previous TUR-P: Oncological, surgical, and functional outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 527.e21-527.e28.	1.6	16
34	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 160-168.	5.4	15
35	Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged >=50 years: a population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 71-77.	3.9	13
36	The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2018, 12, E325-30.	0.6	13

#	ARTICLE	IF	CITATIONS
37	Retrograde ejaculation after holmium laser enucleation of the prostate (HoLEP)â€™Impact on sexual function and evaluation of patient bother using validated questionnaires. <i>Andrology</i> , 2020, 8, 1779-1786.	3.5	13
38	Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 243-249.	1.6	11
39	Contemporary approach to predict early biochemical recurrence after radical prostatectomy: update of the Walz nomogram. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 386-393.	3.9	11
40	Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 81-88.	2.2	11
41	Oncological, functional and perioperative outcomes in transplant patients after radical prostatectomy. <i>World Journal of Urology</i> , 2016, 34, 1101-1105.	2.2	10
42	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e141-e149.	1.9	10
43	Tumor characteristics, oncological and functional outcomes after radical prostatectomy in very young menâ€™s45 years of age. <i>World Journal of Urology</i> , 2020, 38, 95-101.	2.2	8
44	Impact of the estimated blood loss during radical prostatectomy on functional outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 298.e11-298.e17.	1.6	7
45	Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 193-201.	3.9	7
46	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. <i>Experimental and Molecular Pathology</i> , 2018, 105, 50-56.	2.1	6
47	Validation of the current eligibility criteria for focal therapy in men with localized prostate cancer and the role of MRI. <i>World Journal of Urology</i> , 2018, 36, 705-712.	2.2	5
48	Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. <i>European Urology Focus</i> , 2019, 5, 545-549.	3.1	5
49	Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. <i>European Urology Focus</i> , 2019, 5, 568-576.	3.1	5
50	Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. <i>European Urology Focus</i> , 2020, 6, 1213-1219.	3.1	5
51	Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis. <i>Cancers</i> , 2022, 14, 740.	3.7	5
52	Prostate cancer prognosis in men with other malignancies prior to radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 575.e1-575.e7.	1.6	4
53	Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 1.e11-1.e16.	1.6	3
54	Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorganâ€™confined prostate cancer. <i>Prostate</i> , 2022, 82, 949-956.	2.3	3

#	ARTICLE	IF	CITATIONS
55	Oncologic outcomes of organ-confined Gleason grade group 4-5 prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 161.e9-161.e14.	1.6	3
56	External validation of the novel International Society of Urological Pathology (ISUP) Gleason grading groups in a large contemporary Canadian cohort. <i>Canadian Urological Association Journal</i> , 2018, 12, .	0.6	2
57	Anesthetic Technique (Spinal vs. General Anesthesia) in Holmium Laser Enucleation of the Prostate: Retrospective Analysis of Procedural and Functional Outcomes among 1,159 Patients. <i>Urologia Internationalis</i> , 2023, 107, 336-343.	1.3	2
58	Complications after salvage radical prostatectomy: vesicourethral anastomosis leaks and possible prevention. <i>Translational Andrology and Urology</i> , 2017, 6, 994-996.	1.4	1
59	Regression Discontinuity Analysis of Salvage Radiotherapy in Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 817-820.	5.4	1
60	Validation of the updated eighth edition of AJCC for prostate cancer: Removal of pT2 substages – Does extent of tumor involvement matter?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 637.e1-637.e7.	1.6	1